70 related articles for article (PubMed ID: 9120277)
1. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses.
Wu S; Maslanka K; Gorski J
J Immunol; 1997 Apr; 158(7):3221-6. PubMed ID: 9120277
[TBL] [Abstract][Full Text] [Related]
2. T cell immunobiology of alloimmune thrombocytopenias.
Gorski J; Yassai M; Wu S; Maślanka K
Arch Immunol Ther Exp (Warsz); 1998; 46(5):269-75. PubMed ID: 9832065
[TBL] [Abstract][Full Text] [Related]
3. Suppression of the antibody response to a polymorphic peptide from the platelet alloantigen integrin beta3 with low molecular weight antigen arrays.
Watson DC; Reim J; Dintzis HM
J Immunol; 1996 Apr; 156(7):2443-50. PubMed ID: 8786303
[TBL] [Abstract][Full Text] [Related]
4. C-terminal anchoring of a peptide to class II MHC via the P10 residue is compatible with a peptide bulge.
Yassai M; Afsari A; Garlie J; Gorski J
J Immunol; 2002 Feb; 168(3):1281-5. PubMed ID: 11801666
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
6. Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides.
Moro M; Cecconi V; Martinoli C; Dallegno E; Giabbai B; Degano M; Glaichenhaus N; Protti MP; Dellabona P; Casorati G
BMC Immunol; 2005 Dec; 6():24. PubMed ID: 16329759
[TBL] [Abstract][Full Text] [Related]
7. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the alloreactive helper T-cell response to the platelet membrane glycoprotein IIIa (integrin-beta3) in human platelet antigen-1a alloimmunized human platelet antigen-1b1b women.
Sukati H; Bessos H; Barker RN; Urbaniak SJ
Transfusion; 2005 Jul; 45(7):1165-77. PubMed ID: 15987363
[TBL] [Abstract][Full Text] [Related]
9. T cell recognition of MHC class II-associated peptides is independent of peptide affinity for MHC and sodium dodecyl sulfate stability of the peptide/MHC complex. Effects of conservative amino acid substitutions at anchor position 1 of influenza matrix protein19-31.
Wu S; Gorski J; Eckels DD; Newton-Nash DK
J Immunol; 1996 May; 156(10):3815-20. PubMed ID: 8621918
[TBL] [Abstract][Full Text] [Related]
10. A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes.
Gregori S; Trembleau S; Penna G; Gallazzi F; Hammer J; Papadopoulos GK; Adorini L
J Immunol; 1999 Jun; 162(11):6630-40. PubMed ID: 10352280
[TBL] [Abstract][Full Text] [Related]
11. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein.
Calvo-Calle JM; Hammer J; Sinigaglia F; Clavijo P; Moya-Castro ZR; Nardin EH
J Immunol; 1997 Aug; 159(3):1362-73. PubMed ID: 9233633
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR.
Doherty DG; Penzotti JE; Koelle DM; Kwok WW; Lybrand TP; Masewicz S; Nepom GT
J Immunol; 1998 Oct; 161(7):3527-35. PubMed ID: 9759873
[TBL] [Abstract][Full Text] [Related]
13. A mannose 6-phosphate-containing N-linked glycopeptide derived from lysosomal acid lipase is bound to MHC class II in B lymphoblastoid cell lines.
Dustin ML; McCourt DW; Kornfeld S
J Immunol; 1996 Mar; 156(5):1841-7. PubMed ID: 8596035
[TBL] [Abstract][Full Text] [Related]
14. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
[TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
16. A hepatitis C virus (HCV) core protein derived peptide inhibits HCV specific lymphocyte proliferation.
Langhans B; Lechmann M; Ihlenfeldt H; Jung G; Giers G; Schweitzer S; El Bakri M; Sauerbruch T; Spengler U
Eur J Med Res; 2000 Mar; 5(3):115-20. PubMed ID: 10756165
[TBL] [Abstract][Full Text] [Related]
17. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
[TBL] [Abstract][Full Text] [Related]
18. Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes.
Geluk A; van Meijgaarden KE; Roep BO; Ottenhoff TH
J Autoimmun; 1998 Aug; 11(4):353-61. PubMed ID: 9776713
[TBL] [Abstract][Full Text] [Related]
19. Immunodominance does not result from peptide competition for MHC class II presentation.
Lo-Man R; Langeveld JP; Martineau P; Hofnung M; Meloen RH; Leclerc C
J Immunol; 1998 Feb; 160(4):1759-66. PubMed ID: 9469434
[TBL] [Abstract][Full Text] [Related]
20. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Bristol JA; Schlom J; Abrams SI
J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
